Bandy plus (Albendazole)
Bandy plus (Albendazole) is from the family of an anti-worm or anthelmintic drug. It stops recently originated worms (insect larvae) from developing or reproducing in the human body. It is efficient (first line of management) in opposition to: Flatworms trematodes/ Flukes, Tapeworm- Echinococcosis, /cestodes, Nematodes –Roundworm, Hookworms, Whipworms, pinworms or threadworms. In Africa albendazole (contributed by the pharma company GlaxosmithKline) is being administered to take care of lymphatic filariasis as part of attempts to prevent spread of the illness. In sub- Saharan Africa, the drug is administered combined with ivermectin, and in rest of the world, the drug is used together with diethylcarbamazine. In Brazil and other nations is administered to take care of giardiasis.
Bandy plus (Albendazole) prevents the action on tubulin polymerization, effecting in failure of cytoplasmic microtubules.
Absorption: Albendazole is feebly taken in from the gastrointestinal tract; conversely, it is quickly transformed to its principal active form, albendazole sulfoxide, before attaining complete flow. Oily meals improve bioavailability, as suggested by up to a five times boost in plasma absorption in albendazole sulfoxide. Albendazole sulfoxide plasma absorptions vary depending on quantity intake.
Distribution: Albendazole sulfoxide is seventy percent protein bound and broadly dispensed all through the system.
Metabolism After changing in the liver to albendazole sulfoxide, it is additionally transformed to albendazole sulfone and supplementary oxidative metabolites.
Elimination: Albendazole sulfoxide riddance is 8-12 hour. Biliary riddance of albendazole sulfoxide causes biliary absorptions comparable to plasma absorption. Urinary emission is a negligible riddance trail (<1%).
Albendazole Adverse Reactions
Bandy Plus Side Effects
Headache (11 percent); increeased intracranial pressure (2 percent); vertigo/ dizziness, meningeal symptoms (1 percent).
Reversible alopecia (2 percent); allergic reaction which include urticaria and skin rashed (< 1 percent), erythema multiforme; Stevens-Johnson disease ( after marketing).
Stomach pain, vomiting/ nausea (6 percent).
Genitourinary Severe renal problem .
Abnormal LFTs (16 percent); hepatitis ( after marketing).
Agranulocytosis, pancytopenia, granulocytopenia, thrombocytopenia (very uncommon); Leukopenia (less than 1%); aplastic anemia (postmarketing).
Miscellaneous Fever (1%).
Keep an eye on blood cell counts as well as the functioning of the liver at the start of each 28-day cycle of treatment and every 2 week during treatment period. Stop treatment if liver enzymes are considerably amplified.